Steve Schonfeld’s bioAffinity Technologies BIAF Stock Holding History

Steve Schonfeld’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,413	Closed	-$93.5K	–	2624
2026 Q1	$93.5K	Buy	+24,413	New	+$39.4K	﹤0.01%	1901

Other funds holding BIAF

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Steve Schonfeld's BIAF Position: Q2 2026 in Review

Steve Schonfeld sold out of bioAffinity Technologies (BIAF) in Q2 2026, closing a stake of 24,413 shares — an estimated $93.5K sold.

Steve Schonfeld first reported a position in BIAF in Q1 2026 and held it in 1 quarter. The position peaked at $93.5K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

Steve Schonfeld reported no remaining bioAffinity Technologies position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 24,413 bioAffinity Technologies shares in Q2 2026, an estimated $93.5K.
Steve Schonfeld first reported a position in bioAffinity Technologies in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's bioAffinity Technologies position peaked at $93.5K in Q1 2026.
19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.